Tag: CAB-LA

CAB-LA Enjoys High Continuity Rates Among PrEP Users In Zimbabwe

Michael Gwarisa

By Michael Gwarisa The recently introduced long-acting cabotegravir (CAB-LA) for HIV prevention has seen more users returning to get the second dose post their first jab, with data showing that the injectable drug has recorded a continuity rate over 90% since roll out in April, 2024. Currently, the Injectable PrEP is being administered in PrEP study sites in Harare, Mature and Bulawayo and is targeting mainly groups at high risk of HIV, namely Female Sex Workers (FSW), Adolescent Girls and Young Women (AGYW) and Men who have Sex with other…

Read More

Zim readies incorporation of Cabotegravir into local PrEP guidelines

Kuda Pembere

FOLLOWING the approval for use of Cabotegravir (CAB-LA) in Zimbabwe by the Medicines Control Authority of Zimbabwe (MCAZ) last year, the country is expected to have incorporated the World Health Organization (WHO) guidelines of this long-acting HIV preventive method into its own HIV pre-exposure prophylaxis in June. By Kudakwashe Pembere That the WHO guidelines would be incorporated into Zimbabwe’s was revealed by renowned HIV Prevention expert Dr Nyaradzo Mgodi last week in a media science café organized by the Health Communicators Forum (HCF). Zimbabwe is the first African country to…

Read More